pinusolidic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: pinusolidic acid
• 英文别名: (1S,4aR,8aR)-1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid
• 化学式: C₂₀H₂₈O₄
• 分子量: 332.44
• InChiKey: FHQSDRHZGCMBKG-KERRNGMLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  koraienside H 在 β-glucosidase from almonds 、 水 作用下， 反应 48.0h， 生成 L-阿拉伯糖 、 葡萄糖 、 pinusolidic acid
  参考文献：
  名称：

  来自红松树枝的抗神经退行性拉丹二萜糖苷。

  摘要：

  11个新半日花烷型双萜类糖苷，koraiensides A-K（1 - 11），加上两个已知类似物从的细枝分离红松。它们的结构通过 NMR、HRMS 和 ECD 数据、DP4+ 统计分析和水解得到阐明。测试代谢物在 C6 神经胶质瘤细胞中诱导神经生长因子，以评估其潜在的神经保护活性。测量这些化合物在脂多糖 (LPS) 激活的小鼠小胶质细胞 BV2 细胞中产生的一氧化氮水平，以评估它们的抗神经炎症活性。化合物10和13显示出来自 C6 神经胶质瘤细胞的 NGF 分泌诱导作用（分别为 162.3 ± 13.9% 和 162.7 ± 6.9%）。化合物图6显示24.1μM的IC 50值，暗示NO产生的显着抑制。

  DOI：

  10.1021/acs.jnatprod.9b01158

文献信息

• LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF
  申请人：Sun Yat-Sen University

  公开号：EP2857391A1

  公开（公告）日：2015-04-08

  Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.

  本发明提供了各种唇形二萜化合物及其衍生物，用于制备预防或治疗神经退行性疾病的药物组合物。本发明还提供了一种精液生物提取物，其中包含一种或多种唇形二萜化合物及其衍生物，用于制备预防或治疗神经退行性疾病的药物组合物。
• Novel diterpenes from the fruiting body of Antrodia camphorata and pharmaceutical compositions thereof
  申请人：Lai Min-Nan

  公开号：US20080103196A1

  公开（公告）日：2008-05-01

  The present invention relates to novel diterpene compounds isolated from the fruiting body of Antrodia camphorata , especially to the new compounds of following structural formula: and pharmaceutically acceptable salt, solvate, hydrate or biologically active equivalent thereof. The present invention also relates to a pharmaceutical composition containing at least one of the novel diterpene compounds, and a use of the diterpene compound as a neuroprotective agent.
• Novel diterpenes from the fruiting body of antrodia camphorata and pharmaceutical compositions thereof
  申请人：Lai Min-Nan

  公开号：US20090118364A1

  公开（公告）日：2009-05-07

  The present invention relates to novel diterpene compounds isolated from the fruiting body of Antrodia camphorate , especially to the new compounds of following structural formula: and pharmaceutically acceptable salt, solvate, hydrate or biologically active equivalent thereof. The present invention also relates to a pharmaceutical composition containing at least one of the novel diterpene compounds, and a use of the diterpene compound as a neuroprotective agent.
• METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES
  申请人：Su Weiwei

  公开号：US20160082059A1

  公开（公告）日：2016-03-24

  Provided herein is a method for preventing or treating neurodegenerative disease in a subject, comprising administrating to the subject an effective amount of a composition which comprises a semen biotae extract. The neurodegenerative disease is associated with α-synuclein, such as Alzheimer's disease, Parkinson's disease, Huntington disease, or Amyotrophic lateral sclerosis.
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170042912A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.